Complement analysis in the 21st century

被引:98
作者
Mollnes, Tom Eirik [1 ]
Jokiranta, T. Sakari
Truedsson, Lennart
Nilsson, Bo
Rodriguez de Cordoba, Santiago
Kirschfink, Michael
机构
[1] Natl Hosp Norway, Inst Immunol, N-0027 Oslo, Norway
[2] Univ Oslo, Inst Immunol, N-0316 Oslo, Norway
[3] Univ Tromso, Nordland Hosp, Dept Lab Med, N-9001 Tromso, Norway
[4] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland
[5] Univ Helsinki, Huslab, FIN-00014 Helsinki, Finland
[6] Lund Univ, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, S-22100 Lund, Sweden
[7] Univ Uppsala Hosp, Rudbeck Lab, Dept Radiol Oncol & Clin Immunol, Div Clin Immunol, S-75014 Uppsala, Sweden
[8] CSIC, Ctr Invest Biol, Unidad Inmunol, Madrid 6, Spain
[9] Heidelberg Univ, Inst Immunol, D-6900 Heidelberg, Germany
关键词
complement assay; neoepitope; proteomic analyses; genetic analyses;
D O I
10.1016/j.molimm.2007.06.150
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Complement analysis in the clinic is usually associated with the quantification of C3 and C4, measurement of C1-inhibitor and screening for complement activity. These analyses have been available in routine diagnostic laboratories for decades. In recent years, however, the field of complement analysis has expanded considerably, with the introduction of novel assays to detect complement activation products, and spreading still further towards genetic analysis to reveal the basis of complement deficiencies and identify mutations and polymorphisms associated with defined diseases such as atypical haemolytic uraemic syndrome and age related macular degeneration. Here we review the current status of complement analysis, including assays for the quantification of complement activity and complement activation products, together with genetic methods for the detection of deficiencies, mutations and polymorphisms. This is an area where significant developments have been made recently, paralleling the research advances into the role of complement in human disease. It is clear, however, that there is a need for consensus and standardisation of analytical methods. This will be a major challenge for the complement society in the future. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3838 / 3849
页数:12
相关论文
共 114 条
[1]   The role of the complement system in ischemia-reperfusion injury [J].
Arumugam, TV ;
Shiels, IA ;
Woodruff, TM ;
Granger, DN ;
Taylor, SM .
SHOCK, 2004, 21 (05) :401-409
[2]   Bypassing complement: evolutionary lessons and future implications [J].
Atkinson, JP ;
Frank, MM .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) :1215-1218
[3]   MEASUREMENT OF COMPLEMENT ACTIVATION IN RABBIT PLASMA OR SERUM USING MONOCLONAL-ANTIBODIES AGAINST C5A [J].
BERGH, K ;
IVERSEN, OJ .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1989, 29 (03) :333-341
[4]   The effect of phospholipids on the formation of immune complexes between autoantibodies and β2-glycoprotein I or prothrombin [J].
Bevers, EM ;
Zwaal, RFA ;
Willems, GM .
CLINICAL IMMUNOLOGY, 2004, 112 (02) :150-160
[5]  
BLACK MM, 1989, ACTA DERM-VENEREOL, P96
[6]   Antibody microarray-based oncoproteomics [J].
Borrebaeck, Carl A. K. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (08) :833-838
[7]   Mannose-binding lectin: Clinical implications for infection, transplantation, and autoimmunity [J].
Bouwman, Lee H. ;
Roep, Bart O. ;
Roos, Anja .
HUMAN IMMUNOLOGY, 2006, 67 (4-5) :247-256
[8]   PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis [J].
Brodsky, Robert A. ;
Hu, Rong .
LEUKEMIA & LYMPHOMA, 2006, 47 (07) :1215-1221
[9]   Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease [J].
Caprioli, J ;
Castelletti, F ;
Bucchioni, S ;
Bettinaglio, P ;
Bresin, E ;
Pianetti, G ;
Gamba, S ;
Brioschi, S ;
Daina, E ;
Remuzzi, G ;
Noris, M .
HUMAN MOLECULAR GENETICS, 2003, 12 (24) :3385-3395
[10]  
Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297